Perspective
Featured Topics
Lead story
Other featured articles
-
Improving Medicare Advantage by Accounting for Large Differences in Upcoding Across Plans
A two-pronged reform strategy can limit the competitive edge for Medicare Advantage plans that aggressively upcode while lowering overpayments.
Posted in -
Comments to CMS on Proposed Medicare and Medicaid Coverage of Anti-Obesity Medications
Schaeffer Center research shows expanding access to breakthrough anti-obesity medications can broadly generate positive social returns while potentially shrinking health disparities.
Posted in -
Medicare Drug Price Negotiations Need Something New: A Floor
Adding a floor price mechanism would protect valuable innovation and effectively give future generations of patients a seat at the negotiating table.
Posted in -
Medicare Advantage Enrollment Has Surged. Big Savings for Beneficiaries Help Explain Why.
A typical enrollee could save about $140 per month by picking a Medicare Advantage plan over traditional Medicare. Policymakers considering MA reform shouldn’t overlook the program’s greater financial generosity.
Posted in
ADDITIONAL Perspectives
-
Medicare Should Cover Wegovy — but Not Negotiate Its Price
Subjecting Wegovy to price controls would crush innovation and discourage new entrants to this important new class of anti-obesity medications that could help millions of Americans.
Categorized in -
How to Protect Yourself Against Wildfire Smoke: Five Tips in Everyday Language (Updated)
Helpful tips on staying protected from wildfire smoke.
Categorized in -
Comments on Enhancing Coverage of Preventive Services Under the Affordable Care Act
Removing prescribing requirements and cost barriers could significantly improve access to contraception. However, successful implementation will require careful consideration of operational processes.
Categorized in -
Government Needs to Do More to Ensure Obesity Drug Safety
Expanding coverage for anti-obesity medications without reforming compounding regulation will exacerbate problems with counterfeit drugs. The incoming administration should modernize manufacturing techniques, shore up the supply chain and ban compounding of new obesity medications.
Categorized in -
Comments to CMS on Proposed $2 Drug List Model
Transparent, simple plan benefits like the proposed model, as well as transparent cost structures throughout the system, have valuable impacts for the beneficiary and the potential to help align incentives throughout the distribution system.
Categorized in -
Medicare Advantage Costs Taxpayers 22% More Per Enrollee. Here’s How Payment Reform Could Help Close the Gap.
The Medicare Advantage payment system needs a broad reform that aligns insurers’ incentives with the needs of beneficiaries and taxpayers.
Categorized in